Clinical UpdatesbevacizumabERBB2-negative breast cancer
U-BOMB Phase 2 Trial: Promising Activity of Utidelone Plus Bevacizumab in ERBB2-Negative Metastatic Breast Cancer with Active Brain Metastases
By MedXY|Oct 7, 2025
The U-BOMB phase 2 trial demonstrates that the combination of utidelone and bevacizumab shows encouraging efficacy and tolerability in patients with ERBB2-negative metastatic breast cancer and active brain metastases, addressing a critical